TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
about
The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastasesPrognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Disease evolution and heterogeneity in bilateral breast cancer.The fate of BRCA1-related germline mutations in triple-negative breast tumors.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer.Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancerTowards precision medicine: linking genetic and cellular heterogeneity in gastric cancerPrevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
P2860
Q33630343-1B68E8AD-E3BC-4971-ADF8-45CC59983758Q33646271-3B1EE288-9DA6-4972-9F5B-63D885FD2A33Q37447919-8638B6F0-4A4E-4C87-8207-FFE03B94319EQ37596828-F87C491A-A7CB-4496-A46C-41AEFD914E15Q39638185-34B00796-A2F8-4DDF-A07D-268FF45A1A88Q55008104-0BD6DD2C-ED02-48AC-BECD-9BA0ABB5FFFFQ57494109-2E8B84A3-9630-458B-A1E4-B61E397CDD9DQ58695226-8751E801-399B-448F-BCBE-DE4960CCA370Q58744379-B6434E74-13CC-4C7F-8776-CEFAE8086070
P2860
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@en
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@nl
type
label
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@en
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@nl
prefLabel
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@en
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@nl
P2093
P2860
P50
P356
P1433
P1476
TP53 mutations and protein imm ...... eated in the adjuvant setting.
@en
P2093
Aggeliki Lyberopoulou
Angelos Koutras
Charisios Karanikiotis
Christos Christodoulou
Christos Papandreou
Christos Poulios
Dimitrios Bafaloukos
Dimitrios Pectasides
Eleni Timotheadou
Epaminontas Samantas
P2860
P304
32731-32753
P356
10.18632/ONCOTARGET.9022
P407
P577
2016-04-26T00:00:00Z